Contributions of Leukemia Inhibitory Factor Receptor and Oncostatin M Receptor to Signal Transduction in Heterodimeric Complexes with Glycoprotein 130

Leukemia inhibitory factor (LIF), cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M (OSM) lead to heterodimerization of LIF receptor (LIFR) or the OSM-specific receptor (OSMR) with glycoprotein (gp) 130, the common receptor subunit for IL-6-type cytokines. Thereby intracellular signalin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of immunology (1950) 1999-12, Vol.163 (12), p.6651-6658
Hauptverfasser:	Hermanns, Heike M, Radtke, Simone, Haan, Claude, Schmitz-Van de Leur, Hildegard, Tavernier, Jan, Heinrich, Peter C, Behrmann, Iris
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens, CD - genetics Antigens, CD - metabolism Antigens, CD - physiology Carcinoma, Hepatocellular COS Cells Cytokine Receptor gp130 Cytoplasm - metabolism Cytoplasm - physiology Dimerization DNA-Binding Proteins - metabolism Gene Expression Regulation - immunology glycoprotein gp130 Growth Inhibitors Humans Interleukin-6 Jak kinase Janus Kinase 1 Janus Kinase 2 Leukemia Inhibitory Factor Leukemia Inhibitory Factor Receptor alpha Subunit Lymphokines Macromolecular Substances Membrane Glycoproteins - genetics Membrane Glycoproteins - metabolism Membrane Glycoproteins - physiology Oncostatin M Peptide Fragments - genetics Peptide Fragments - physiology Peptides - genetics Peptides - metabolism Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins Receptors, Cytokine - genetics Receptors, Cytokine - metabolism Receptors, Cytokine - physiology Receptors, Interleukin - metabolism Receptors, Interleukin-5 Receptors, Oncostatin M Receptors, OSM-LIF Signal Transduction - genetics Signal Transduction - immunology Stat1 protein STAT1 Transcription Factor Stat3 protein Trans-Activators - metabolism Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!